Hard to swallow

December 15, 2006

I see that investors in Pfizer are stunned by a fall of more than £15 billion in the value of the drug company after trials of the cholesterol-lowering drug Torcetrapib were stopped.

In clinical trials there were 60 per cent more deaths in the group taking the animal-tested drug than in the group given a placebo. Perhaps investors should support our campaign.

Pat Rattigan
Director, British Anti-Vivisection Association

Please Login or Register to read this article.

Register to continue

Get a month's unlimited access to THE content online. Just register and complete your career summary.

Registration is free and only takes a moment. Once registered you can read a total of 3 articles each month, plus:

  • Sign up for the editor's highlights
  • Receive World University Rankings news first
  • Get job alerts, shortlist jobs and save job searches
  • Participate in reader discussions and post comments
Please Login or Register to read this article.